Teva Pharmaceutical Industries Stock Earnings Reports

Teva reported a solid start to 2026 driven by continued strength in its innovative portfolio (AUSTEDO, UZEDY, AJOVY). Q1 revenue was about $4.0B (down 1% in local currency vs. Q1'25, up 7% excluding Japan divestment and generic REVLIMID), adjusted EBITDA was $1.1B (+2%), non-GAAP EPS $0.53 (+2%), free cash flow rose ~76% to ~$188–200M, and net debt/EBITDA is ~2.42x. Management reiterated its Pivot to Growth strategy and 2027 targets (mid-single-digit revenue growth, ~30% non-GAAP operating margin, <2x net debt/EBITDA, cash-to-earnings ~80%).

Major operational highlights and pipeline/m&a: Teva announced the acquisition of Emalex (upfront $700M + up to $200M milestones) to in-license ecopipam for pediatric Tourette syndrome; management emphasizes strategic fit with Teva's CNS capabilities and expects orphan dynamics and high gross margin (~80%) for the product. Multiple near-term R&D milestones are expected in 2026 (7+ readouts including duvakitug maintenance, anti–IL-15 vitiligo in H1, celiac and other readouts, DARI Phase III events by year-end, futility analysis for emrusolmin). Olanzapine LAI EU submission was just filed and FDA review is ongoing with a hoped-for approval this year.

Generics/biosimilars: Global generics were down as expected (impact of generic REVLIMID and Japan divestment). Biosimilars are a growing contributor—Teva now has 11 biosimilars on market with many more launches planned through 2027, increasing the innovative/biosimilar mix and gross margin profile over time.

Financial/capital allocation: Emalex acquisition is expected to be treated as an asset deal such that the $700M upfront will be recorded through R&D in P&L; ~ $75M of additional OpEx in 2026 (starting Q3) is expected. Management reaffirmed 2026 guidance on an underlying basis excluding Emalex and expects Emalex to be accretive to non-GAAP EPS starting 2028 while having no change to the 2027 leverage target. The Board has authorized planning for a potential share repurchase program (timing/size TBD). Teva remains on track for the $700M transformation cost savings program (on track to realize ~2/3 by end-2026).

Risks/notes: Channel inventory timing (destocking) and IRA-related dynamics could affect AUSTEDO quarterly patterns (noted uncertainty around Q4/2026). Geopolitical developments in the Middle East are being monitored but currently have no material impact on operations or guidance. Management emphasizes discipline on M&A and capital allocation, focusing inorganic acquisitions in CNS and organic development in immunology while retaining flexibility.